Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · IEX Real-Time Price · USD
1.060
-0.020 (-1.85%)
Apr 25, 2024, 4:00 PM EDT - Market closed
Adaptimmune Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for ADAP stock have an average target of 5.50, with a low estimate of 1.00 and a high estimate of 10. The average target predicts an increase of 418.87% from the current stock price of 1.06.
Analyst Consensus: Buy
* Price targets were last updated on Aug 10, 2023.
Analyst Ratings
The average analyst rating for ADAP stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell Maintains $2 → $1 | Sell | Maintains | $2 → $1 | -5.66% | Aug 10, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +843.40% | Aug 10, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +843.40% | Jun 5, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +843.40% | Jun 2, 2023 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +843.40% | May 26, 2023 |
Financial Forecast
Revenue This Year
71.44M
from 60.28M
Increased by 18.52%
Revenue Next Year
65.24M
from 71.44M
Decreased by -8.68%
EPS This Year
-0.28
from -0.54
EPS Next Year
-0.38
from -0.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 97.6M | 95.2M | 86.4M | 94.5M | 131.3M |
| Avg | 71.4M | 65.2M | 53.8M | 91.8M | 127.5M |
| Low | 58.5M | 27.8M | 26.5M | 88.2M | 122.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 61.9% | 33.3% | 32.5% | 75.8% | 43.0% |
| Avg | 18.5% | -8.7% | -17.6% | 70.8% | 38.9% |
| Low | -2.9% | -61.0% | -59.4% | 64.1% | 33.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.06 | -0.02 | -0.07 |
| Avg | -0.28 | -0.38 | -0.45 |
| Low | -0.54 | -0.69 | -0.64 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.